PMID- 15778730
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20071115
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 35
IP  - 10
DP  - 2005 May
TI  - Haplotype mismatched transplantation using high doses of peripheral blood CD34+ 
      cells together with stratified conditioning regimens for high-risk adult acute 
      myeloid leukemia patients: a pilot study in a single Korean institution.
PG  - 959-64
AB  - A total of 11 high-risk Korean acute myeloid leukemia (AML) patients received 
      stem cell transplantation from human leukocyte antigen (HLA) haploidentical 
      donors. Specifically, for eight patients with 2-3 mismatched antigens and 
      bidirectional vectors, we used a newly designed conditioning regimen that 
      consists of total body irradiation, busulfex, ATG, and fludarabine. The median 
      number of CD34+ cells infused was 15.4 x 10(6)/kg (range, 8-21.2). These patients 
      received neither graft-versus-host disease (GvHD) prophylaxis nor post 
      transplantation G-CSF. All of the patients who were followed up for a median of 6 
      months (range, 17 days-28 months) showed stable primary engraftment and had no 
      acute GvHD or transplant-related mortality for 100 days post transplant. Three 
      patients with high-risk or refractory disease eventually died in relapse, even 
      with GvH-directed NK alloreactivity. However, the patients in complete remission 
      (CR), with the exception of one patient who is alive at 18 months EFS, died at 4, 
      6, and 8 months post transplantation due to infections that were associated with 
      delayed immune recovery. Our findings suggest that haploidentical transplantation 
      represents a feasible treatment for patients with high-risk AML in CR, provided 
      that a plan for the enhancement of immune recovery is implemented.
FAU - Kim, H-J
AU  - Kim HJ
AD  - Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic 
      Stem Cell Transplantation Center, The Catholic University of Korea College of 
      Medicine, Seoul, Korea.
FAU - Min, W-S
AU  - Min WS
FAU - Kim, Y-J
AU  - Kim YJ
FAU - Kim, D-W
AU  - Kim DW
FAU - Lee, J-W
AU  - Lee JW
FAU - Kim, C-C
AU  - Kim CC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antigens, CD34)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD34/*analysis
MH  - Child
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - *Haplotypes
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Male
MH  - Middle Aged
MH  - Peripheral Blood Stem Cell Transplantation/*methods
MH  - Pilot Projects
MH  - *Transplantation Conditioning
MH  - Treatment Outcome
EDAT- 2005/03/22 09:00
MHDA- 2005/07/22 09:00
CRDT- 2005/03/22 09:00
PHST- 2005/03/22 09:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2005/03/22 09:00 [entrez]
AID - 1704900 [pii]
AID - 10.1038/sj.bmt.1704900 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2005 May;35(10):959-64. doi: 10.1038/sj.bmt.1704900.